KALV
KalVista Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.00
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +13.1%
- EBIT
- +8.6%
- Net income
- +10.4%
- EPS
- +12.5%
- Free cash flow
- +45.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026